Aussie Biotech Biota Closer To Resolution With GSK On Relenza Suit
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Biota Holdings' lawsuit with GlaxoSmithKline over antiviral influenza vaccine Relenza (zanamivir) is getting closer to resolution, the Melbourne, Australia-based biotech told PharmAsia News